Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protective effect of continuous esketamine use in open heart surgery under cardiopulmonary bypass
ChiCTR2100048377Phase 4Not yet recruiting
- Sponsor
- Weihai Municipal Hospital
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in Cardiac valve disease (VHD) (2 arms), sponsored by Weihai Municipal Hospital. Primary endpoints: Heart rate and Blood pressure. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
Cardiac valve disease (VHD)
Beyond the preview
Go deeper on ChiCTR2100048377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048377.